Rosuvastatin 20 mg once daily bedtime. 2 months
Checking Date & Time
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Searching PubMed
rosuvastatin adverse effects safety
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of the side effects and safety profile of Rosuvastatin 20 mg once daily at bedtime.
Rosuvastatin 20 mg — Side Effects & Safety Profile
Rosuvastatin 20 mg is classified as a high-intensity statin (alongside rosuvastatin 40 mg and atorvastatin 40–80 mg). Its long half-life (~19 hours) means bedtime dosing offers no pharmacokinetic advantage over other times of day (unlike shorter-acting statins), but it is acceptable.
1. Musculoskeletal Effects (Most clinically important)
| Effect | Frequency | Action |
|---|---|---|
| Myalgia / muscle aches | Up to 10–20% (complaints) | Reassess; many are nocebo-related |
| Asymptomatic CK elevation | ~5% | No action if <10× ULN and asymptomatic |
| Symptomatic myopathy (pain + weakness) | <0.1% | Stop statin |
| Rhabdomyolysis | <0.1% (0–2.2 per 1000 person-years) | Stop immediately; hospitalise; hydrate |
Up to 75–80% of patients who report statin intolerance can actually tolerate a statin when given blinded — the "nocebo" effect accounts for a significant proportion of reported muscle symptoms. — Goldman-Cecil Medicine
Red flags requiring immediate cessation: severe muscle pain/weakness, or dark/tea-coloured urine (myoglobinuria).
Risk factors for myopathy:
- Reduced GFR / CKD
- Hypothyroidism
- Genetic variant in SLCO1B1 (encodes OATP1B1 transporter)
- Drug interactions (see below)
2. Hepatic Effects
- Mild AST/ALT elevation (up to 3× ULN): occurs in some patients; often transient and not associated with clinical hepatotoxicity — can continue with monitoring.
- Persistent ALT/AST >3× ULN or jaundice / ALT >5× ULN: stop the drug, evaluate for other causes.
- Patients with underlying liver disease or heavy alcohol use are at higher risk.
Monitoring: Baseline LFTs → recheck at 1–2 months → then every 12 months if stable. — Katzung's Pharmacology, 16th Ed.
3. New-Onset Diabetes
- Small but significant increase in type 2 diabetes incidence, particularly in patients with pre-existing insulin resistance, obesity, or prediabetes.
- Fasting glucose increases minimally in most; a smaller subset develop frank insulin resistance.
- Management: Continue statin (cardiovascular benefit outweighs risk), encourage weight loss, physical activity, and treat diabetes if it develops. — Goldman-Cecil Medicine
4. CNS / Other Effects
- Infrequent: headache, fatigue, dizziness
- Rare: hemorrhagic stroke (slightly increased signal, particularly at high doses in patients with prior stroke)
- GI: mild — nausea, constipation, dyspepsia (uncommon)
- Dermatological: rash, urticaria (rare)
5. Drug Interactions (Rosuvastatin-specific)
Rosuvastatin is metabolised by CYP2C9 (not CYP3A4 like simvastatin/atorvastatin), so it is less affected by macrolide antibiotics, azole antifungals, and grapefruit juice. However:
| Interacting Drug | Effect |
|---|---|
| CYP2C9 inhibitors (ketoconazole, metronidazole, amiodarone, cimetidine, sulfinpyrazone) | ↑ Rosuvastatin plasma levels → ↑ myopathy risk |
| Cyclosporine | Significantly ↑ rosuvastatin levels |
| Fibrates (especially gemfibrozil) | ↑ Myopathy/rhabdomyolysis risk |
| Antacids (aluminium/magnesium) | May reduce rosuvastatin absorption |
| Warfarin | Rosuvastatin may ↑ INR |
6. Monitoring Summary at 2 Months
| Parameter | Recommendation |
|---|---|
| Fasting lipid panel | Check to assess LDL response |
| LFTs (AST/ALT) | Recheck at 1–2 months post initiation |
| CK | Only if muscle symptoms present; not routine |
| Fasting glucose / HbA1c | Especially in pre-diabetic patients |
| Symptoms | Ask specifically for muscle pain, weakness, dark urine |
Recent Evidence Note
A 2026 Lancet meta-analysis (CTT Collaboration, PMID: 41655587) reassessed adverse effects attributed to statins in blinded RCTs — confirming that many labelled side effects have significant nocebo contributions and that the absolute risks of serious harms (myopathy, hepatotoxicity) are low relative to cardiovascular benefits.
Sources: Katzung's Basic & Clinical Pharmacology 16th Ed. | Goldman-Cecil Medicine | Bradley & Daroff's Neurology | Fitzpatrick's Dermatology | Cholesterol Treatment Trialists Meta-Analysis 2026 (PMID: 41655587)
This is a shared conversation. Sign in to Orris to start your own chat.